98%
921
2 minutes
20
Completing parts of trematode life cycles in the laboratory is a useful way to obtain experimentally infected hosts and identify how specific aspects of parasitism influence host ecology and behavior. However, a lack of knowledge about host specificity and other factors that influence prevalence can hamper those efforts. Echinostoma trivolvis lineage c is a genetically distinct member of the E. trivolvis species complex that is known only from DNA sequences from adult and larval stages recovered from naturally infected muskrats (Ondatra zibethicus) and the marsh pondsnail (Ladislavella elodes), respectively. We determined the effect of host species/morphotype, host size, and miracidial dose on the infection success in potential first intermediate hosts. In the laboratory, we exposed 2 freshwater snail species (L. elodes and Planorbella duryi) and a morphological variant of L. elodes (formerly known as Stagnicola reflexa) to 2 miracidia to determine first intermediate host use. Among these 3 snail groups, we also tested the effect of host size on infection success with 3 size classes (1-5 mm, 5-10 mm, and 10-15 mm). Within 1 host species, L. elodes, we compared the effect of 2 doses (2 and 5 miracidia) and 3 size classes on infection success. At a dose of 2 miracidia, rediae and cercariae developed within 1 host species, L. elodes, as well as the S. reflexa morphotype, although infection success varied according to host size. At a dose of 5 miracidia, infection success increased in small and medium-size L. elodes relative to the low dose group. Our results confirm the first intermediate host species observed in nature but indicate that prevalence is influenced by host species morphotype, host size, and parasite dose. To obtain more infected snails, our experiments suggest exposing small and medium-size L. elodes snails to 5 miracidia. This research encourages further use of E. trivolvis lineage c in the laboratory to explore aspects of host-parasite interactions such as parasite-modified behavior.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1645/24-37 | DOI Listing |
Antimicrob Agents Chemother
September 2025
GSK, Collegeville, Pennsylvania, USA.
Gepotidacin, a novel, bactericidal, first-in-class triazaacenaphthylene antibacterial, was noninferior to nitrofurantoin in two pivotal trials (EAGLE-2 and EAGLE-3) in females with uncomplicated urinary tract infections (uUTIs). Using pooled data, gepotidacin activity and clinical efficacy were evaluated for subsets of molecularly characterized isolates in the microbiological Intent-to-Treat population. The subsets of isolates were characterized based on phenotypic/MIC criteria; all microbiological failure isolates were also characterized.
View Article and Find Full Text PDFAntimicrob Agents Chemother
September 2025
GSK, London, United Kingdom.
Two recent Phase 3 trials demonstrated the efficacy of gepotidacin compared with nitrofurantoin to treat uncomplicated urinary tract infections (uUTIs) in females. Pretreatment urine specimens were obtained from all participants. Based on pooled trial data (treatment groups combined), central laboratory culture results identified 1,421 (45%) participants with ≥1 baseline qualifying (≥10 CFU/mL) uropathogen (i.
View Article and Find Full Text PDFKnee Surg Sports Traumatol Arthrosc
September 2025
International Joint Center, Acibadem Mehmet Ali Aydınlar University, Istanbul, Turkey.
Despite undisputed success of orthopaedic procedures, surgical site infections (SSI) such as periprosthetic joint infection (PJI) continues to compromise the outcome and result in major clinical and economic burden. The overall rate of infection is expected to rise in the future resulting in significant associated mortality and morbidity. Traditional concepts have largely attributed the source of PJI to exogenous pathogens.
View Article and Find Full Text PDFAllergol Immunopathol (Madr)
September 2025
Department of Emergency Medicine, Tuzla State Hospital, İstanbul, Turkey.
Desensitization is an immunological process that creates temporary tolerance to a drug, which disappears once treatment is discontinued. Ciprofloxacin is a commonly used antibiotic, particularly for chronic lung diseases, yet there are very few desensitization protocols for it. Two ciprofloxacin desensitization schemes were developed a long time ago.
View Article and Find Full Text PDFAllergol Immunopathol (Madr)
September 2025
Department of Allergy and Immunology, University of Health Sciences, Süreyyapaşa Training and Research Hospital, Istanbul, Turkey.
Background: Antituberculosis drugs can cause hypersensitivity reactions that interrupt treatment and increase morbidity. Early identification and management are essential to prevent complications and drug resistance.
Objective: To evaluate the clinical characteristics, risk factors, and outcomes of antituberculosis drug-induced hypersensitivity reactions over a 10-year period in a tertiary referral center.